• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

    3/10/26 8:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Joshua Jackson is joined by Gritty to take the body check off the ice.

    AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310693422/en/

    Joshua Jackson teams up with Gritty and AstraZeneca to encourage fans to Get Body Checked Against Cancer. Photo Credit: Marie Lombardo, photographer

    Joshua Jackson teams up with Gritty and AstraZeneca to encourage fans to Get Body Checked Against Cancer. Photo Credit: Marie Lombardo, photographer

    To help bring the message to life in a way that feels accessible, engaging and familiar, Joshua Jackson is joined by Gritty, the iconic mascot of the Philadelphia Flyers, to capture why it's so important to get body checked. The pairing draws a parallel between a well-timed body check on the ice and a timely check-in with a doctor—both moments when taking action can make a meaningful difference.

    Mohit Manrao, Senior Vice President, Head of US Oncology, AstraZeneca, said: "Beating cancer takes a team—and action saves lives. By teaming up with Joshua Jackson and Gritty, we're calling on fans to get informed and get screened. With an estimated 65% of Americans behind on recommended screenings1 and cancer rates rising among people under 50,2 now is the time to talk to your doctor about your risk and the screenings that are right for you. Don't wait—get body checked."

    Actor/Producer Joshua Jackson said: "People close to me have been diagnosed with cancer, and I'm at an age where I should know my own risks. So, if you watched me when I was a kid and you were a kid, it's time to talk to your doctor about getting screened. Together with AstraZeneca and my good friend, Gritty, we don't want you to wait to talk to your doctor."

    The Get Body Checked Against Cancer campaign encourages people to take control of their health by talking with their doctors about their cancer risk factors and whether cancer screenings are right for them. The campaign supports Hockey Fights Cancer™, a joint initiative of the National Hockey League (NHL) and the National Hockey League Players' Association (NHLPA) powered by the V Foundation for Cancer Research. Since 2023, AstraZeneca has proudly served as the first-ever official national partner of Hockey Fights Cancer.

    Gritty, mascot of the Philadelphia Flyers, said: "There's a lot of important checks out there—poke checks, paychecks, rain checks—but here's a reality check…Get body checked. Checkmate."

    To date, AstraZeneca has donated $1.1 million to Hockey Fights Cancer through the V Foundation to help fund game-changing cancer research.

    For more information about what screenings may be right for you, to find a screening provider near you and for a list of questions you and your loved ones can ask your doctor, visit Getbodychecked.com. Follow AstraZeneca on Instagram and YouTube to see all the content with Joshua Jackson and Gritty.

    NHL and the NHL Shield are registered trademarks and Hockey Fights Cancer name and logo and NHL Mascots are trademarks of the National Hockey League. NHL and NHL team marks are the property of the NHL and its teams. © 2026 NHL. All Rights Reserved.

    NHLPA and the NHLPA logo are registered trademarks of the National Hockey League Players' Association. © NHLPA. All Rights Reserved.

    Notes

    AstraZeneca in Oncology

    AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

    The Company focuses on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.

    AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

    AstraZeneca

    AstraZeneca (NYSE:AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca's website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.

    References

    1. Meister K. 65% of Americans 21 years of age and older report not being up to date on at least one routine cancer screening. Prevent Cancer Foundation. Published February 21, 2023. Accessed February 27, 2025. https://preventcancer.org/news/65-of-americans-21-years-of-age-and-older-report-not-being-up-to-date-on-at-least-one-routine-cancer-screening/
    2. Shiels MS, Haque AT, Berrington de Gonzalez A, et al. Trends in cancer incidence and mortality rates in early-onset and older-onset age groups in the United States, 2010-2019. American Association for Cancer Research. Published July 23 2025. Accessed February 25, 2026. https://aacrjournals.org/cancerdiscovery/article-abstract/15/7/1363/763190/Trends-in-Cancer-Incidence-and-Mortality-Rates-in?redirectedFrom=fulltext

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260310693422/en/

    Media Inquiries

    Fiona Cookson, +1 212 814-3923

    Lauren-Jei McCarthy, +1 347 918-7001



    US Media Mailbox: [email protected]

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Citigroup
    10/27/2025Buy
    Jefferies
    10/16/2025Hold → Sell
    Deutsche Bank
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    3/10/26 8:07:58 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    3/10/26 7:37:46 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    3/6/26 8:11:49 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

    Joshua Jackson is joined by Gritty to take the body check off the ice. AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310693422/en/Joshua Jackson teams up with Gritty and AstraZen

    3/10/26 8:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1

    Approval based on KOMET Phase III trial results which showed 20% objective response rate in tumour size reductionMISSISSAUGA, ON, March 9, 2026 /CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).1 The approval by Health Canada was based on positive results from KOMET, the largest and only placebo-controlled global Phase III trial in this patient population. Data were pr

    3/9/26 8:05:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

    Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 If approved, AstraZeneca and Daiichi Sankyo's ENHERTU has the potential to become a new standard of care in this early breast cancer setting AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. The Food and Drug Administration (FDA) grants Priority Review to

    3/9/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Financials

    Live finance-specific insights

    View All

    AstraZeneca results: FY and Q4 2025

    Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

    2/10/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/4/22 9:06:48 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/3/21 1:13:21 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care